Ethypharm India has signed an out-licensing and supply contract for Tramadol 50 mg Flashtab to Ranbaxy, the company reported.
Tramadol is indicated for moderate-to-severe pain in trauma cases and is currently one of the four most commonly prescribed analgesics in the world. It is also used as an adjunct therapy in the treatment of cancer patients.
"Ranbaxy has strong presence in the pain management segment," said Sanjeev Dani, Ranbaxy's regional director for India and the Middle East. "The introduction [of Tramadol in the Indian market] will mean speedier pain relief to patients."